Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling? (vol 26, pg 211, 2023)

被引：0

|

作者：

Chen, Ethan

Ling, Alexander L.

Reardon, David A.

Chiocca, E. Antonio

机构：

来源：

NEURO-ONCOLOGY | 2024年 / 26卷 / 04期

关键词：

D O I：

10.1093/neuonc/noad241

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：779 / 779

页数：1

相关论文

共 50 条

[31] Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (vol 399, pg 2113, 2022)
Danese, S.
Vermeire, S.
Zhou, W.
LANCET, 2022, 400 (10357): : 996 - 996
[32] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
Mignot, E.
Mayleben, D.
Fietzeet, I
LANCET NEUROLOGY, 2022, 21 (03):
[33] Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials (vol 3, pg 355, 2015)
Castro, M.
Zangrilli, J.
Wechsler, M. E.
LANCET RESPIRATORY MEDICINE, 2016, 4 (10): : E50 - E50
[34] Active immunotherapeutics forum-Advance phase III active immunotherapy programs Just how well did the pre-clinical and early clinical trials translate? Case Studies: With the benefit of hindsight, what are the three biggest lessons learned from pre-clinical and early clinical trials? Meeting report from Barcelona, May 12 2011
Colon, Will
HUMAN VACCINES, 2011, 7 (10): : 1019 - 1020
[35] Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a phase 3 vaccine efficacy trial (vol 22, pg 968, 2006)
Jobes, David V.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (01) : 181 - 181
[36] Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial (vol 402, pg 798, 2023)
Becker, J. C.
Ugurel, S.
Leiter, U.
LANCET, 2023, 402 (10411): : 1422 - 1422
[37] Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial (vol 402, pg 859, 2023)
Lafayette, R.
Kristensen, J.
Stone, A.
LANCET, 2023, 402 (10405): : 850 - 850
[38] Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial (vol 18, pg 755, 2023)
Mao, W.
Chen, R.
Zhang, J.
Zheng, M.
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 119 - 121
[39] An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose (vol 92, pg 455, 2023)
Jessen, Bart A.
Cornwell, Paul
Redmond, Sean
Visalli, Thomas
Lemper, Marie
Bunch, Todd
Hart, Timothy
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 1 - 1
[40] Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial (vol 83, pg 212, 2023)
Boegemann, Martin
Shore, Neal D.
Smith, Matthew R.
Tammela, Teuvo L. J.
Ulys, Albertas
Vjaters, Egils
Polyakov, Sergey
Jievaltas, Mindaugas
Luz, Murilo
Alekseev, Boris
Lebret, Thierry
Schostak, Martin
Verholen, Frank
Le Berre, Marie-Aude
Srinivasan, Shankar
Ortiz, Jorge
Mohamed, Ateesha F.
Sarapohja, Toni
Fizazi, Karim
EUROPEAN UROLOGY, 2023, 83 (02) : E60 - E60

← 1 2 3 4 5 →